The Conversation (0)
BioVie confirmed enrollment of the first patient in the Company’s mid-stage clinical trial of BIV201.
BioVie (OTCQB:BIVI) confirmed enrollment of the first patient in the Company’s mid-stage clinical trial of BIV201.
As quoted in the press release:
The initial trial is being led by Jasmohan Bajaj, MD, MS, study site principal investigator (PI) at the McGuire Research Institute in Richmond, VA.
The study titled Safety and pharmacodynamic activity of low-dose terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites requiring recurrent large volume paracentesis is an open-label prospective study in a cohort of 6 patients who are refractory to, or intolerant of, diuretic therapy.
Click here to read the full press release.
Source: www.marketwired.com
